A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS).

Trial Profile

A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS).

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2013

At a glance

  • Drugs Tirasemtiv (Primary) ; Riluzole
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors Cytokinetics
  • Most Recent Events

    • 22 Aug 2013 Pooled results of trials CY4024 and CY4025 published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, according to a Cytokinetics media release.
    • 10 Dec 2012 Results were presented at the 23rd International Symposium on ALS/MND, according to a Cytokinetics media release.
    • 13 Mar 2012 Actual patient number (50) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top